Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

[1] Robinson JG(2015)The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence European heart journal. 36 2110-2118

[2] Stone NJ(2006)Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation. 113 791-798

[3] Lloyd-Jones DM(2009)Prognostic models with competing risks: methods and application to coronary risk prediction Epidemiology. 20 555-561

[4] Leip EP(2011)Dynamic microsimulation models for health outcomes: a review Med Decis Making. 31 10-18

[5] Larson MG(2017)Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease The New England journal of medicine. 376 1713-1722

[6] D'Agostino RB(2015)Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment European heart journal. 36 2975-2983

[7] Beiser A(2015)Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials BMC Med. 13 123-781

[8] Wilson PW(1999)Second manifestations of ARTerial disease (SMART) study: rationale and design European journal of epidemiology. 15 773-41

[9] Wolf PA(2011)Epidemiology and risk profile of heart failure Nat Rev Cardiol. 8 30-953

[10] Levy D(2006)Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study European heart journal. 27 949-49

[1] Robinson JG(2015)The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence European heart journal. 36 2110-2118

[2] Stone NJ(2006)Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation. 113 791-798

[3] Lloyd-Jones DM(2009)Prognostic models with competing risks: methods and application to coronary risk prediction Epidemiology. 20 555-561

[4] Leip EP(2011)Dynamic microsimulation models for health outcomes: a review Med Decis Making. 31 10-18

[5] Larson MG(2017)Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease The New England journal of medicine. 376 1713-1722

[6] D'Agostino RB(2015)Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment European heart journal. 36 2975-2983

[7] Beiser A(2015)Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials BMC Med. 13 123-781

[8] Wilson PW(1999)Second manifestations of ARTerial disease (SMART) study: rationale and design European journal of epidemiology. 15 773-41

[9] Wolf PA(2011)Epidemiology and risk profile of heart failure Nat Rev Cardiol. 8 30-953

[10] Levy D(2006)Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study European heart journal. 27 949-49